Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Tectonic Therapeutic announced the completion of enrollment for its APEX Phase 2 clinical trial evaluating TX45 in patients with PH-HFpEF. The global, randomized, double-blind, placebo-controlled trial enrolled 191 patients across 14 countries, with 137 patients (72%) in the enriched CpcPH population with PVR >3 WU.
Key figures
- Drug Name
- TX45
- Phase Of Trial
- Phase 2
- Countries
- 14
- Enrolled patients
- 191
- Topline results date
- early Q1 2027
- Enriched population pct
- 72%
- Mean baseline pvr overall
- 4.2 WU
- Mean baseline pvr enriched
- 5.2 WU
- Enriched population patients
- 137
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.